Patents by Inventor Robert F Bruns, Jr.

Robert F Bruns, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS
    Publication number: 20110059935
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: August 25, 2010
    Publication date: March 10, 2011
    Applicant: Azevan Pharmaceuticals, Inc
    Inventors: Robert F. Bruns, JR., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • ?-lactamyl vasopressin V antagonists
    Patent number: 7268125
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 11, 2007
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Robert F. Bruns, Jr., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • ?-Lactamyl vasopressin VAntagonists
    Patent number: 7119083
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: October 11, 2002
    Date of Patent: October 10, 2006
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Robert F. Bruns, Jr., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • Beta-lactamyl vasopressin v1aantagonists
    Publication number: 20040266750
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: June 15, 2004
    Publication date: December 30, 2004
    Inventors: Robert F. Bruns Jr, Christophe D.G. Guillon, Ned E. Heindel, Gary A. Koppel, Marvin J. Miller
  • Non-peptidyl vasopressin V1A antagonists
    Patent number: 6610680
    Abstract: This invention provides substituted 2-(azetidinon-1-yl) acetic acid derivatives of Formula II for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: August 26, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
    Patent number: 6562862
    Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen,  or  wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: May 13, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6521611
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl) acetic acid derivatives of Formula I for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: February 18, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin D G Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Indolyl neuropeptide Y receptor antagonists
    Patent number: 6245761
    Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.
    Type: Grant
    Filed: August 29, 1996
    Date of Patent: June 12, 2001
    Assignee: Eli Lilly and Company
    Inventors: Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
  • Non-peptidyl vasopressin V1a antagonists
    Patent number: 6204260
    Abstract: This invention provides methods and 2-(azetidin-2-on-1-yl)acetic acid derivatives for the antagonism of the vasopressin V1a receptor.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: March 20, 2001
    Assignee: Eli Lilly and Company
    Inventors: Robert F Bruns, Jr., Robin DG Cooper, Bruce A Dressman, David C Hunden, Stephen W Kaldor, Gary A Koppel, John R Rizzo, Jeffrey J Skelton, Mitchell I Steinberg
  • Heterocyclic neuropeptide Y receptor antagonists
    Patent number: 5663192
    Abstract: This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: September 2, 1997
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Method of treating anxiety by inhibiting physiological conditions associated with an excess of neuropeptide Y
    Patent number: 5576337
    Abstract: A method of inhibiting the physiological disorder anxiety associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: November 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Methods of treating depression by inhibiting physiological conditions associated with an excess of neuropeptide Y
    Patent number: 5567715
    Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: October 22, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Methods of treating obesity by inhibiting physiological conditions associated with an excess of neuropeptide Y
    Patent number: 5567714
    Abstract: A method of inhibiting obesity, a physiological disorder associated with an excess of neuropeptide Y, or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: October 22, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Methods of inhibiting physiological conditions associated with an excess of bradykinin
    Patent number: 5545641
    Abstract: A method of inhibiting a physiological condition associated with an excess of bradykinin comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: August 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Naphthyl bradykinin receptor antagonists
    Patent number: 5514675
    Abstract: This invention provides methods of treating a physiological disorder associated with an excess of bradykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Use of bengothiophenls to treat pain due to an excess of neuropeptide y
    Patent number: 5504094
    Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: April 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Naphthyl tachykinin receptor antagonists to treat physiological conditions
    Patent number: 5491140
    Abstract: This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn